Literature DB >> 11289471

Corneal advanced glycation end products increase in patients with proliferative diabetic retinopathy.

E Sato1, F Mori, S Igarashi, T Abiko, M Takeda, S Ishiko, A Yoshida.   

Abstract

OBJECTIVE: To evaluate corneal advanced glycation end product (AGE) fluorescence in patients with diabetes and in healthy control subjects. RESEARCH DESIGN AND METHODS: Corneal autofluorescence was measured in 26 eyes of 26 patients with type 2 diabetes (mean age 57.0 years; mean disease duration 12.2 years; mean HbA1c 7.1%) and 13 eyes of 13 healthy age-matched control subjects (mean age 57.9 years). The patients with type 2 diabetes were divided into the following groups: patients without diabetic retinopathy (DR), patients without proliferative diabetic retinopathy (PDR), and patients with PDR. Corneal autofluorescence was measured by fluorophotometry with the wavelength that is characteristic of AGE fluorescence (excitation and emission 360-370 nm and 430-450 nm, respectively). We defined peak corneal autofluorescence levels as corneal AGE fluorescence values. We compared the corneal AGE fluorescence values in the four groups.
RESULTS: In the PDR group (11.9 +/- 3.9 arbitrary units [mean +/- SD]), the corneal AGE fluorescence values were significantly higher compared with the control subjects (6.9 +/- 1.3 arbitrary units), the patients without DR (7.4 +/- 2.1 arbitrary units), and the patients without PDR (6.9 +/- 2.2 arbitrary units) (P < 0.05).
CONCLUSIONS: We found that corneal AGEs may increase in patients with diabetes and PDR compared with control subjects, patients without DR, and patients without PDR. In the patients with PDR, increased corneal AGEs may play a role in diabetic keratopathy.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11289471     DOI: 10.2337/diacare.24.3.479

Source DB:  PubMed          Journal:  Diabetes Care        ISSN: 0149-5992            Impact factor:   19.112


  19 in total

1.  Immunohistochemical localization of advanced glycation end products in pinguecula.

Authors:  Yuichi Kaji; Tetsuro Oshika; Shiro Amano; Fumiki Okamoto; Wakako Koito; Seikoh Horiuchi
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2005-07-21       Impact factor: 3.117

2.  Proteinase and growth factor alterations revealed by gene microarray analysis of human diabetic corneas.

Authors:  Mehrnoosh Saghizadeh; Andrei A Kramerov; Jian Tajbakhsh; Annette M Aoki; Charles Wang; Ning-Ning Chai; Julia Y Ljubimova; Takako Sasaki; Gabriel Sosne; Marc R J Carlson; Stanley F Nelson; Alexander V Ljubimov
Journal:  Invest Ophthalmol Vis Sci       Date:  2005-10       Impact factor: 4.799

Review 3.  Ocular complications of diabetes mellitus.

Authors:  Nihat Sayin; Necip Kara; Gökhan Pekel
Journal:  World J Diabetes       Date:  2015-02-15

Review 4.  Corneal alteration and pathogenesis in diabetes mellitus.

Authors:  Han Zhao; Yan He; Yue-Rong Ren; Bai-Hua Chen
Journal:  Int J Ophthalmol       Date:  2019-12-18       Impact factor: 1.779

Review 5.  Dietary hyperglycemia, glycemic index and metabolic retinal diseases.

Authors:  Chung-Jung Chiu; Allen Taylor
Journal:  Prog Retin Eye Res       Date:  2010-09-22       Impact factor: 21.198

6.  Involvement of advanced glycation end products, oxidative stress and nuclear factor-kappaB in the development of diabetic keratopathy.

Authors:  Junghyun Kim; Chan-Sik Kim; Eunjin Sohn; Il-Ha Jeong; Hyojun Kim; Jin Sook Kim
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2010-11-23       Impact factor: 3.117

7.  Elevated serum levels of N(epsilon)-carboxymethyl-lysine, an advanced glycation end product, are associated with proliferative diabetic retinopathy and macular oedema.

Authors:  B O Boehm; S Schilling; S Rosinger; G E Lang; G K Lang; R Kientsch-Engel; P Stahl
Journal:  Diabetologia       Date:  2004-07-17       Impact factor: 10.122

Review 8.  Too sweet: Problems of protein glycation in the eye.

Authors:  Eloy Bejarano; Allen Taylor
Journal:  Exp Eye Res       Date:  2018-08-24       Impact factor: 3.467

9.  Simple non-invasive assessment of advanced glycation endproduct accumulation.

Authors:  R Meerwaldt; R Graaff; P H N Oomen; T P Links; J J Jager; N L Alderson; S R Thorpe; J W Baynes; R O B Gans; A J Smit
Journal:  Diabetologia       Date:  2004-07-09       Impact factor: 10.122

Review 10.  Diabetic keratopathy and treatment by modulation of the opioid growth factor (OGF)-OGF receptor (OGFr) axis with naltrexone: a review.

Authors:  Patricia J McLaughlin; Joseph W Sassani; Matthew S Klocek; Ian S Zagon
Journal:  Brain Res Bull       Date:  2009-08-14       Impact factor: 4.077

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.